Abstract

EVIDENCE BASED MANAGEMENT OF ALZHEIMER’S DISEASE

Ghantasala Lakshmi Priya*, Natta Prathibha and Kantamaneni Padmalatha

Abstract

Alzheimer’s disease is a neurological brain disorder, that slowly destroys the memory and thinking skills and eventually the ability to carry the simple tasks. Evidence based Management of Alzheimer’s disease is demanding, and the drugs target to improve the cognitive and behavioral symptoms at various stages to get the desired therapeutic outcomes had been implemented. Up to this date, symptomatic therapy, exists for Alzheimer’s disease. The goal of therapy is to reduce or stabilize the rate of cognitive decline by initiation of cholinesterase inhibitor include rivastigmine, donepezil treats mild to moderate alzheimer’s disease. The N-methyl -Daspartate antagonist, memantine, may be used as monotherapy or in combination of cholinesterase inhibitors for moderate to severe alzheimer’s disease. During this therapy, cognitive and behavior status should be monitored over 6 months interval and pharmacologic treatment of alzheimer’s disease should be continued to relieve the symptoms and improve the quality of life for the person and their family and caregivers.

Keywords: Alzheimer’s disease, non-steroidal anti-inflammatory drugs, diagnostic and statistical manual of mental disorders, quality of life, evidence, cognitive function, randomized controlled trails.